This is a welcome text with instructions

Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date
on information about hepatitis and to answer some of our web site and training audience questions.
People are encouraged to submit questions and post comments.

Be sure to check out our other blog: Hepatitis & Tattoos

Alan Franciscus
Editor-inChief
HCV Advocate
HBV Advocate


Friday, February 17, 2012

Gilead Suffers First Hep C Drug Setback

FOSTER CITY, Calif. (TheStreet) --Gilead Sciences(GILD_) just had its first stumble in the race to develop an all-oral therapy for hepatitis C.

A two-drug regimen of Gilead's experimental GS-7977 plus ribavirin failed to suppress the hepatitis C virus in a group of difficult-to-treat patients who had also failed prior therapy, Gilead announced Friday.

Read more...
Posted by HCV Advocate at 12:15 PM
Labels: , , , ,

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)